Stocks · News reference

TD Cowen Maintains Hold on Quanterix, Raises Price Target to $3.5

Oct 13, 2026, 3:50 PMBenzinga Newsdesk

TD Cowen analyst Dan Brennan maintains Quanterix (NASDAQ:QTRX) with a Hold and raises the price target from $3 to $3.5.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 22, 2026, 1:03 PM
Quanterix Announces Webinar on Spatial Proteomics and Transcriptomics Integration
Quanterix is hosting a multi-speaker webinar focused on the integration of spatial proteomics and spatial transcriptomics to enhance biological insights from tissue samples.
QTRX
BenzingaOct 7, 2026, 12:02 PMBenzinga Newsdesk
Quanterix, Innovita Biological Technology Receives Regulatory Nods From China For Quanterix SIMOA Technology, Neurology Biomarker Testing
Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced
QTRX
Globenewswire IncSep 22, 2026, 5:00 PMDelveinsight
Global Alzheimer’s Disease Biomarker Market Poised for Phenomenal Expansion at a Growth Rate of ~9% by 2034 | DelveInsight
The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.
RHHBY QTRX ABT TMO SMMNY